Modulation of pristane-induced arthritis by mycobacterial antigens.
Several prominent mycobacterial protein antigens involved in antibody and T cell responses have been identified as members of highly conserved heat shock protein families. In particular, immune responses to the mycobacterial 65 kD heat shock protein (hsp65) have been implicated in the pathogenesis of autoimmune diseases both in experimental animal models and in man. Additionally, hsp65 has been shown to modulate the course of autoimmune disease in such experimental animal systems. In this report, we have examined the synthesis of heat shock proteins by a fast growing mycobacterial strain, M. vaccae, in heat stressed cultures and used the pristane induced arthritis model to investigate the immunoprophylactic and immunotherapeutic potential of heat killed M. vaccae. Heat shock of M. vaccae cultures at 48 degrees C demonstrated a 43-fold increase in hsp65 over that expressed at 37 degrees C. It is therefore suggested that heat killed M. vaccae contains sufficient hsp that can be presented in the context of appropriate adjuvant properties for use as an effective immunomodulatory agent. Immunisation experiments with M. vaccae revealed that protection or exacerbation of pristane induced arthritis was dependent on the dose (given in an oil or aqueous suspension), route and time of immunisation. In addition, it was demonstrated that the development of arthritis correlated with high levels of agalactosyl IgG and that "protected" animals had significantly depressed levels.
Thompson
S J
SJ
Department of Pathology, University of Bristol, UK.
Butcher
P D
PD
Patel
V K
VK
Rook
G A
GA
Stanford
J
J
van der Zee
R
R
Elson
C J
CJ
D000818:Animals; D000942:Antigens, Bacterial / Q000627:therapeutic use*; D001168:Arthritis / Q000139:chemically induced / Q000517:prevention & control* / Q000628:therapy*; D001345:Autoradiography; D002273:Carcinogens; D003720:Densitometry; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D004591:Electrophoresis, Polyacrylamide Gel; D005620:Freund's Adjuvant / Q000494:pharmacology; D006360:Heat-Shock Proteins / Q000276:immunology / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000096:biosynthesis; D007167:Immunotherapy; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009161:Mycobacterium / Q000276:immunology* / Q000378:metabolism; D013729:Terpenes; D014611:Vaccination
D000942:Antigens, Bacterial; D002273:Carcinogens; D006360:Heat-Shock Proteins; D007074:Immunoglobulin G; D013729:Terpenes; C064155:agalactosyl IGG; C009042:pristane; D005620:Freund's Adjuvant